- Home
- JDZG vs APLM Comparison
JDZG vs APLM Comparison
Compare JDZG & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JDZG
- APLM
- Stock Information
- Founded
- JDZG 2020
- APLM 2016
- Country
- JDZG China
- APLM United States
- Employees
- JDZG N/A
- APLM N/A
- Industry
- JDZG Other Consumer Services
- APLM Blank Checks
- Sector
- JDZG Real Estate
- APLM Finance
- Exchange
- JDZG Nasdaq
- APLM Nasdaq
- Market Cap
- JDZG 15.2M
- APLM 12.3M
- IPO Year
- JDZG 2024
- APLM N/A
- Fundamental
- Price
- JDZG $0.58
- APLM $8.00
- Analyst Decision
- JDZG
- APLM Strong Buy
- Analyst Count
- JDZG 0
- APLM 2
- Target Price
- JDZG N/A
- APLM $425.00
- AVG Volume (30 Days)
- JDZG 100.1K
- APLM 4.5K
- Earning Date
- JDZG 11-27-2024
- APLM 03-25-2025
- Dividend Yield
- JDZG N/A
- APLM N/A
- EPS Growth
- JDZG N/A
- APLM N/A
- EPS
- JDZG 0.06
- APLM N/A
- Revenue
- JDZG $2,334,771.00
- APLM $2,101,000.00
- Revenue This Year
- JDZG N/A
- APLM N/A
- Revenue Next Year
- JDZG N/A
- APLM N/A
- P/E Ratio
- JDZG $9.45
- APLM N/A
- Revenue Growth
- JDZG 52.08
- APLM 70.54
- 52 Week Low
- JDZG $0.45
- APLM $6.20
- 52 Week High
- JDZG $15.08
- APLM $75.00
- Technical
- Relative Strength Index (RSI)
- JDZG N/A
- APLM 56.02
- Support Level
- JDZG N/A
- APLM $6.36
- Resistance Level
- JDZG N/A
- APLM $8.60
- Average True Range (ATR)
- JDZG 0.00
- APLM 0.50
- MACD
- JDZG 0.00
- APLM 0.27
- Stochastic Oscillator
- JDZG 0.00
- APLM 75.00
About JDZG JIADE LIMITED Common stock
Jiade Ltd Ltd is engaged in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platforms and auxiliary solutions. The Group offers pre-enrollment guidance on school/selection and application development, training for entrance exams, and assistance in the application process. The Group also offers offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance in the People's Republic of China.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.